The significant interest in semi-solid systems for the potential of extended release profiles has prompted researchers to develop alternative encapsulating systems.
An innovative biotechnology company exploring novel therapeutics for neuroscience indications had developed a promising new chemical entity for the treatment of a severe pediatric genetic disease. However, numerous drug delivery challenges threatened the realization of the Fast Track status designation they had received due to promising early stage results. By leveraging a softgel technology, the customer was able to overcome a number of potential hurdles and expeditiously enter the Phase II/III clinical trial.
A commercial stage medical technology company has developed SMART Softgels featuring a special shell to release quickly while still preventing evaporative loss during and after manufacturing.
Due to their poor oral bioavailability, oligosaccharides are formulated as solutions or suspensions and delivered by invasive intravenous (IV) or subcutaneous injection.
This white paper explores best practices in SaaS selection and incorporation into laboratory practices that enable organizations to focus on their core competencies while utilizing best-of-breed software.
Continued Process Verification (CPV), Process Analytical Technology (PAT) and Quality by Design (QbD), are driving pharma to improve product and process quality and efficiency.
This article explains how using an Octet-based Fc receptor panel may help developers achieve a faster assessment of monoclonal antibody functionality, well before the final molecule is selected.
The choice of potential technology transfer partners can be bewildering. Mike Valazza, Vice President Business Development, Drug Delivery Solutions at Catalent Pharma Solutions, shares some of the factors that should be taken into account when making this decision.
If current manufacturing practices are followed to handle small batches of API on industrial size machines, it results in handling difficulties and lower product yield.
Biotech Millennium found that by clearly defining workflows and implementing a highly configurable notebook, it could move its entire discovery organization to a single ELN system.
|
|
|
|
|
|
|
|
|